Molecular Biology Reports

, Volume 38, Issue 8, pp 4847–4853 | Cite as

TP53 codon 72 polymorphism and colorectal cancer susceptibility: a meta-analysis

  • Jing-Jun Wang
  • Yuan Zheng
  • Liang Sun
  • Li Wang
  • Peng-Bo Yu
  • Jian-Hua Dong
  • Lei Zhang
  • Jing Xu
  • Wei Shi
  • Yu-Chun Ren
Article

Abstract

Colorectal cancer constitutes a significant proportion of the global burden of cancer morbidity and mortality. A number of studies have been conducted to explore whether TP53 codon 72 polymorphism is associated with colorectal cancer susceptibility. However, controversial results were obtained. In order to derive a more precise estimation of the relationship, we systematically searched Medline, Google scholar, and Ovid database for studies reported before May 2010. A total of 3603 colorectal cancer cases and 5524 controls were included. TP53 codon 72 polymorphism was not associated with colorectal cancer risk in all genetic models (for dominant model: OR = 0.99, 95% CI: 0.86–1.15; for recessive model: OR = 1.00, 95% CI: 0.81–1.23; for Arg/Pro vs. Arg/Arg: OR = 1.00, 95% CI: 0.87–1.15; for Pro/Pro vs. Arg/Arg: OR = 0.97, 95% CI: 0.76–1.25). In the subgroup analyses by ethnic groups and sources of controls, no significant associations were found in all models. Taken together, this meta-analysis suggested that the biologically usefulness of TP53 codon 72 polymorphism as a selection marker in colorectal cancer susceptibility may be very limited.

Keywords

TP53 Codon 72 Colorectal cancer Meta-analysis 

References

  1. 1.
    Moghaddam AA, Woodward M, Huxley R (2007) Obesity and risk of colorectal cancer: a meta-analysis of 31 studies with 70, 000 events. Cancer Epidemiol Biomarkers Prev 16:2533–2547. doi:10.1158/1055-9965.EPI-07-0708 PubMedCrossRefGoogle Scholar
  2. 2.
    Matsuo K, Suzuki T, Ito H, Hosono S, Kawase T et al (2009) Association between an 8q24 locus and the risk of colorectal cancer in Japanese. BMC Cancer 9:379. doi:10.1186/1471-2407-9-379 PubMedCrossRefGoogle Scholar
  3. 3.
    Rustgi AK (2007) The genetics of hereditary colon cancer. Genes Dev 21:2525–2538. doi:10.1101/gad.1593107 PubMedCrossRefGoogle Scholar
  4. 4.
    Zhuo XL, Cai L, Xiang ZL, Zhuo WL, Wang Y et al (2009) TP53 codon 72 polymorphism contributes to nasopharyngeal cancer susceptibility: a meta-analysis. Arch Med Res 40:299–305. doi:10.1016/j.arcmed.2009.03.006 PubMedCrossRefGoogle Scholar
  5. 5.
    Levine AJ (1997) p53, the cellular gatekeeper for growth and division. Cell 88:323–331PubMedCrossRefGoogle Scholar
  6. 6.
    Dumont P, Leu JI, Della Pietra AC 3rd, George DL, Murphy M (2003) The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 33:357–365. doi:10.1038/ng1093 PubMedCrossRefGoogle Scholar
  7. 7.
    Thomas M, Kalita A, Labrecque S, Pim D, Banks L et al (1999) Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol 19:1092–1100PubMedGoogle Scholar
  8. 8.
    Langerod A, Bukholm IR, Bregard A, Lonning PE, Andersen TI et al (2002) The TP53 codon 72 polymorphism may affect the function of TP53 mutations in breast carcinomas but not in colorectal carcinomas. Cancer Epidemiol Biomarkers Prev 11:1684–1688PubMedGoogle Scholar
  9. 9.
    Olschwang S, Laurent-Puig P, Vassal A, Salmon RJ, Thomas G (1991) Characterization of a frequent polymorphism in the coding sequence of the Tp53 gene in colonic cancer patients and a control population. Hum Genet 86:369–370PubMedCrossRefGoogle Scholar
  10. 10.
    Kawajiri K, Nakachi K, Imai K, Watanabe J, Hayashi S (1993) Germ line polymorphisms of p53 and CYP1A1 genes involved in human lung cancer. Carcinogenesis 14:1085–1089PubMedCrossRefGoogle Scholar
  11. 11.
    Sjalander A, Birgander R, Athlin L, Stenling R, Rutegard J et al (1995) P53 germ line haplotypes associated with increased risk for colorectal cancer. Carcinogenesis 16:1461–1464PubMedCrossRefGoogle Scholar
  12. 12.
    Murata M, Tagawa M, Kimura M, Kimura H, Watanabe S et al (1996) Analysis of a germ line polymorphism of the p53 gene in lung cancer patients; discrete results with smoking history. Carcinogenesis 17:261–264PubMedCrossRefGoogle Scholar
  13. 13.
    Wang NM, Tsai CH, Yeh KT, Chen SJ, Chang JG (1999) P53 codon 72 Arg polymorphism is not a risk factor for carcinogenesis in the Chinese. Int J Mol Med 4:249–252PubMedGoogle Scholar
  14. 14.
    Sayhan N, Yazici H, Budak M, Bitisik O, Dalay N (2001) P53 codon 72 genotypes in colon cancer. Association with human papillomavirus infection. Res Commun Mol Pathol Pharmacol 109:25–34PubMedGoogle Scholar
  15. 15.
    Hamajima N, Matsuo K, Suzuki T, Nakamura T, Matsuura A et al (2002) No associations of p73 G4C14-to-A4T14 at exon 2 and p53 Arg72Pro polymorphisms with the risk of digestive tract cancers in Japanese. Cancer Lett 181:81–85PubMedCrossRefGoogle Scholar
  16. 16.
    Gemignani F, Moreno V, Landi S, Moullan N, Chabrier A et al (2004) A TP53 polymorphism is associated with increased risk of colorectal cancer and with reduced levels of TP53 mRNA. Oncogene 23:1954–1956. doi:10.1038/sj.onc.1207305 PubMedCrossRefGoogle Scholar
  17. 17.
    Schneider-Stock R, Boltze C, Peters B, Szibor R, Landt O et al (2004) Selective loss of codon 72 proline p53 and frequent mutational inactivation of the retained arginine allele in colorectal cancer. Neoplasia 6:529–535. doi:10.1593/neo.04178 PubMedCrossRefGoogle Scholar
  18. 18.
    Kruger S, Bier A, Engel C, Mangold E, Pagenstecher C et al (2005) The p53 codon 72 variation is associated with the age of onset of hereditary non-polyposis colorectal cancer (HNPCC). J Med Genet 42:769–773. doi:10.1136/jmg.2004.028506 PubMedCrossRefGoogle Scholar
  19. 19.
    Sotamaa K, Liyanarachchi S, Mecklin JP, Jarvinen H, Aaltonen LA et al (2005) p53 codon 72 and MDM2 SNP309 polymorphisms and age of colorectal cancer onset in Lynch syndrome. Clin Cancer Res 11:6840–6844. doi:10.1158/1078-0432.CCR-05-1139 PubMedCrossRefGoogle Scholar
  20. 20.
    Koushik A, Tranah GJ, Ma J, Stampfer MJ, Sesso HD et al (2006) p53 Arg 72 Pro polymorphism and risk of colorectal adenoma and cancer. Int J Cancer 119:1863–1868. doi:10.1002/ijc.22057 PubMedCrossRefGoogle Scholar
  21. 21.
    Lima JM, Serafim PV, Silva ID, Forones NM (2006) Role of the genetic polymorphism of p53 (codon 72) gene in colorectal cancer. Arq Gastroenterol 43:8–13PubMedCrossRefGoogle Scholar
  22. 22.
    Perez LO, Abba MC, Dulout FN, Golijow CD (2006) Evaluation of p53 codon 72 polymorphism in adenocarcinomas of the colon and rectum in La Plata, Argentina. World J Gastroenterol 12:1426–1429PubMedGoogle Scholar
  23. 23.
    Perfumo C, Bonelli L, Menichini P, Inga A, Gismondi V et al (2006) Increased risk of colorectal adenomas in Italian subjects carrying the p53 PIN3 A2-Pro72 haplotype. Digestion 74:228–235. doi:10.1159/000100966 PubMedCrossRefGoogle Scholar
  24. 24.
    Tan XL, Nieters A, Hoffmeister M, Beckmann L, Brenner H et al (2007) Genetic polymorphisms in TP53, nonsteroidal anti-inflammatory drugs and the risk of colorectal cancer: evidence for gene-environment interaction? Pharmacogenet Genomics 17:639–645. doi:10.1097/FPC.0b013e3280d5121c PubMedCrossRefGoogle Scholar
  25. 25.
    Zhu ZZ, Wang AZ, Jia HR, Jin XX, He XL et al (2007) Association of the TP53 codon 72 polymorphism with colorectal cancer in a Chinese population. Jpn J Clin Oncol 37:385–390. doi:10.1093/jjco/hym034 PubMedCrossRefGoogle Scholar
  26. 26.
    Dakouras A, Nikiteas N, Papadakis E, Perakis M, Valis D et al (2008) P53Arg72 homozygosity and its increased incidence in left-sided sporadic colorectal adenocarcinomas, in a Greek-Caucasian population. Anticancer Res 28:1039–1043PubMedGoogle Scholar
  27. 27.
    Csejtei A, Tibold A, Varga Z, Koltai K, Ember A et al (2008) GSTM, GSTT and p53 polymorphisms as modifiers of clinical outcome in colorectal cancer. Anticancer Res 28:1917–1922PubMedGoogle Scholar
  28. 28.
    Cao Z, Song JH, Park YK, Maeng EJ, Nam SW et al (2009) The p53 codon 72 polymorphism and susceptibility to colorectal cancer in Korean patients. Neoplasma 56:114–118PubMedCrossRefGoogle Scholar
  29. 29.
    Mammano E, Belluco C, Bonafe M, Olivieri F, Mugianesi E et al (2009) Association of p53 polymorphisms and colorectal cancer: modulation of risk and progression. Eur J Surg Oncol 35:415–419. doi:10.1016/j.ejso.2008.03.003 PubMedCrossRefGoogle Scholar
  30. 30.
    Mojtahedi Z, Haghshenas MR, Hosseini SV, Fattahi MJ, Ghaderi A (2010) p53 codon 72 polymorphism in stomach and colorectal adenocarcinomas in Iranian patients. Indian J Cancer 47:31–34. doi:10.4103/0019-509X.58856 PubMedCrossRefGoogle Scholar
  31. 31.
    Sameer AS, Shah ZA, Syeed N, Banday MZ, Bashir SM et al (2010) TP53 Pro47Ser and Arg72Pro polymorphisms and colorectal cancer predisposition in an ethnic Kashmiri population. Genet Mol Res 9:651–660. doi:10.4238/vol9-2gmr751 PubMedCrossRefGoogle Scholar
  32. 32.
    Rohlfs RV, Weir BS (2008) Distributions of Hardy-Weinberg equilibrium test statistics. Genetics 180:1609–1616. doi:10.1534/genetics.108.088005 PubMedCrossRefGoogle Scholar
  33. 33.
    Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21:1539–1558. doi:10.1002/sim.1186 PubMedCrossRefGoogle Scholar
  34. 34.
    Tobias A (1999) Assessing the influence of a single study in the meta-analysis estimate. Stata Tech Bull 8:15–17Google Scholar
  35. 35.
    Tominaga T, Iwahashi M, Takifuji K, Hotta T, Yokoyama S et al (2010) Combination of p53 codon 72 polymorphism and inactive p53 mutation predicts chemosensitivity to 5-fluorouracil in colorectal cancer. Int J Cancer 126:1691–1701. doi:10.1002/ijc.24929 PubMedGoogle Scholar
  36. 36.
    Katkoori VR, Jia X, Shanmugam C, Wan W, Meleth S et al (2009) Prognostic significance of p53 codon 72 polymorphism differs with race in colorectal adenocarcinoma. Clin Cancer Res 15:2406–2416. doi:10.1158/1078-0432.CCR-08-1719 PubMedCrossRefGoogle Scholar
  37. 37.
    Zhu ZZ, Liu B, Wang AZ, Jia HR, Jin XX et al (2008) Association of p53 codon 72 polymorphism with liver metastases of colorectal cancers positive for p53 overexpression. J Zhejiang Univ Sci B 9:847–852. doi:10.1631/jzus.B0820100 PubMedCrossRefGoogle Scholar
  38. 38.
    Etienne-Grimaldi MC, Formento JL, Francoual M, Francois E, Formento P et al (2008) K-Ras mutations and treatment outcome in colorectal cancer patients receiving exclusive fluoropyrimidine therapy. Clin Cancer Res 14:4830–4835. doi:10.1158/1078-0432.CCR-07-4906 PubMedCrossRefGoogle Scholar
  39. 39.
    Lung FW, Lee TM, Shu BC, Chang FH (2004) p53 codon 72 polymorphism and susceptibility malignancy of colorectal cancer in Taiwan. J Cancer Res Clin Oncol 130:728–732. doi:10.1007/s00432-004-0605-4 PubMedCrossRefGoogle Scholar
  40. 40.
    Jones JS, Chi X, Gu X, Lynch PM, Amos CI et al (2004) p53 polymorphism and age of onset of hereditary nonpolyposis colorectal cancer in a Caucasian population. Clin Cancer Res 10:5845–5849. doi:10.1158/1078-0432.CCR-03-0590 PubMedCrossRefGoogle Scholar
  41. 41.
    Liang Z, Liu F, Luo Y (1995) Detection of the expression of P21, P53, P185 proteins and the mutation of ras, p53 genes in colorectal adenoma and carcinoma. Zhonghua Bing Li Xue Za Zhi 24:352–355PubMedGoogle Scholar
  42. 42.
    Contu SS, Agnes G, Damin AP, Contu PC, Rosito MA et al (2009) Lack of correlation between p53 codon 72 polymorphism and anal cancer risk. World J Gastroenterol 15:4566–4570PubMedCrossRefGoogle Scholar
  43. 43.
    Xi YG, Ding KY, Su XL, Chen DF, You WC et al (2004) p53 polymorphism and p21WAF1/CIP1 haplotype in the intestinal gastric cancer and the precancerous lesions. Carcinogenesis 25:2201–2206. doi:10.1093/carcin/bgh229 PubMedCrossRefGoogle Scholar
  44. 44.
    Kruger S, Engel C, Bier A, Silber AS, Gorgens H et al (2007) The additive effect of p53 Arg72Pro and RNASEL Arg462Gln genotypes on age of disease onset in Lynch syndrome patients with pathogenic germline mutations in MSH2 or MLH1. Cancer Lett 252:55–64. doi:10.1016/j.canlet.2006.12.006 PubMedCrossRefGoogle Scholar
  45. 45.
    Akisik E, Yazici H, Dalay N (2010) ARLTS1, MDM2 and RAD51 gene variations are associated with familial breast cancer. Mol Biol Rep. doi:10.1007/s11033-010-0113-3
  46. 46.
    Wang L, He G, Zhang P, Wang X, Jiang M et al. (2010) Interplay between MDM2, MDMX, Pirh2 and COP1: the negative regulators of p53. Mol Biol Rep. doi:10.1007/s11033-010-0099-x
  47. 47.
    Xian L, Zhao J, Wang J, Fang Z, Peng B et al (2010) p53 Promotes proteasome-dependent degradation of oncogenic protein HBx by transcription of MDM2. Mol Biol Rep 37:2935–2940. doi:10.1007/s11033-009-9855-1 PubMedCrossRefGoogle Scholar
  48. 48.
    Wu M, Mao C, Chen Q, Cu XW, Zhang WS (2010) Serum p53 protein and anti-p53 antibodies are associated with increased cancer risk: a case-control study of 569 patients and 879 healthy controls. Mol Biol Rep 37:339–343. doi:10.1007/s11033-009-9744-7 PubMedCrossRefGoogle Scholar
  49. 49.
    Nathan SS, Pereira BP, Zhou YF, Gupta A, Dombrowski C et al (2009) Elevated expression of Runx2 as a key parameter in the etiology of osteosarcoma. Mol Biol Rep 36:153–158. doi:10.1007/s11033-008-9378-1 PubMedCrossRefGoogle Scholar
  50. 50.
    Zhao S, Zhang J, Zhang X, Dong X, Sun X (2008) Arsenic trioxide induces different gene expression profiles of genes related to growth and apoptosis in glioma cells dependent on the p53 status. Mol Biol Rep 35:421–429. doi:10.1007/s11033-007-9102-6 PubMedCrossRefGoogle Scholar
  51. 51.
    Yuan J, Tang W, Luo K, Chen X, Gu X et al (2006) Cloning and characterization of the human gene DERP6, which activates transcriptional activities of p53. Mol Biol Rep 33:151–158. doi:10.1007/s11033-006-6273-5 PubMedCrossRefGoogle Scholar
  52. 52.
    Hu Z, Li X, Yuan R, Ring BZ, Su L (2010) Three common TP53 polymorphisms in susceptibility to breast cancer, evidence from meta-analysis. Breast Cancer Res Treat 120:705–714. doi:10.1007/s10549-009-0488-9 PubMedCrossRefGoogle Scholar
  53. 53.
    Yan L, Zhang D, Chen C, Mao Y, Xie Y et al (2009) TP53 Arg72Pro polymorphism and lung cancer risk: a meta-analysis. Int J Cancer 125:2903–2911. doi:10.1002/ijc.24603 PubMedCrossRefGoogle Scholar
  54. 54.
    Klug SJ, Ressing M, Koenig J, Abba MC, Agorastos T et al (2009) TP53 codon 72 polymorphism and cervical cancer: a pooled analysis of individual data from 49 studies. Lancet Oncol 10:772–784. doi:10.1016/S1470-2045(09)70187-1 PubMedCrossRefGoogle Scholar
  55. 55.
    Zhu Y, Wang J, He Q, Zhang JQ (2010) Association of p53 codon 72 polymorphism with prostate cancer: a meta-analysis. Mol Biol Rep. doi:10.1007/s11033-010-0269-x
  56. 56.
    Tang NP, Wu YM, Wang B, Ma J (2010) Systematic review and meta-analysis of the association between P53 codon 72 polymorphism and colorectal cancer. Eur J Surg Oncol 36:431–438. doi:10.1016/j.ejso.2010.03.010 PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2010

Authors and Affiliations

  • Jing-Jun Wang
    • 1
  • Yuan Zheng
    • 1
  • Liang Sun
    • 2
  • Li Wang
    • 1
  • Peng-Bo Yu
    • 1
  • Jian-Hua Dong
    • 1
  • Lei Zhang
    • 1
  • Jing Xu
    • 1
  • Wei Shi
    • 1
  • Yu-Chun Ren
    • 1
  1. 1.Department of Center for Disease Control and Prevention of Shaanxi ProvinceXi’anPeople’s Republic of China
  2. 2.Department of Center for Disease Control and Prevention of FuyangFuyangChina

Personalised recommendations